- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
Scientific evidence is essential for policies and programmes to advance the vision of UNAIDS of zero HIV infections, zero discrimination and zero AIDS-related deaths. New scientific information is becoming available at a rapid pace, and many of the findings are potentially important to guide future action against AIDS. To ensure this, UNAIDS has access to the latest scientific developments; a UNAIDS Scientific Expert Panel was established to advise UNAIDS on major new scientific discoveries and research evidence as well as research gaps and strategic AIDS research needs. The Scientific Expert Panel comprises more than 40 scientists from around the world with expertise in a wide range of disciplines, including epidemiology, behavioural science, virology, diagnostics, pathogenesis, immunology, treatment, prevention and cure.
There has been a rapid increase in the number of people living with HIV in Myanmar over the last decade, the majority of who are eligible for treatment. Alongside this increase has been an effort by the ministry of health to rapidly scale up provision of treatment in order to reduce HIV-related illnesses and deaths.
However, Myanmar has an ambitious national strategic goal of providing ART to 106,058 people by the end of 2016. The health system in Myanmar is already stretched, and to achieve this goal, innovation in ART delivery will be required in-order to ensure that ART is provided close to communities, without compromising quality.
The report finds that prices of older HIV drugs continue to decline, while newer drugs remain largely priced out of reach. This is in large part because pharmaceutical corporations maintain monopolies that block price-lowering generic competition.
Today, the lowest available price for a quality-assured, World Health Organization-recommended first-line one-pill-a-day combination is US$100 per person per year (tenofovir/emtricitabine/efavirenz). This is a decrease of 26 per cent since MSF last recorded the lowest price for first-line treatment at US$136 in 2014. For a WHO-recommended second-line regimen, the lowest available price is now US$286 per person per year (zidovudine/lamivudine + atazanavir/ritonavir) – an 11 per cent decrease from US$322 two years ago.
The Global Plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive (Global Plan) was launched in June 2011. It prioritizes the 22 countries1 that, in 2009, accounted for 90% of the global number of pregnant women living with HIV who were in need of services to prevent mother-to-child transmission of HIV. This report summarizes the history and development of the Global Plan, its achievements in reaching ambitious goals, lessons learned and directions for future progress to end new HIV infections among children.
Keywords: HIV, infections, children, prevention, antiretroviral medicines, pregnant women, breastfeeding
Antimicrobial resistance (AMR) has become one of the biggest threats to global health and endangers other major priorities, such as human development. All around the world, many common infections are becoming resistant to the antimicrobial medicines used to treat them, resulting in longer illnesses and more deaths. At the same time, not enough new antimicrobial drugs, especially antibiotics, are being developed to replace older and increasingly ineffective ones.
Global leaders will meet at the United Nations General Assembly in New York in September 2016 to commit to fighting antimicrobial resistance together. This is only the fourth time in the history of the UN that a health topic is discussed at the General Assembly (HIV, noncommunicable diseases, and Ebola were the others). Heads of State and Heads of Delegations are expected to address the seriousness and scope of the situation and to agree on sustainable, multisectoral approaches to addressing antimicrobial resistance.
Keywords: WHO, AMR, Antimicrobial Resistance, High-level Meeting
2015 confirmed a significant recent trend in the flagship WHO Model List of Essential Medicines with groundbreaking new treatments for hepatitis C and a variety of cancers included in the list despite their high prices. The list also included five new medicines for multidrug resistant tuberculosis (TB), among other updates. Traditionally considered a tool for developing countries to use as a guide for national medicines selection, the WHO Essential Medicines List is increasingly seen as a tool to increase access globally.
The 10th Asia-Pacific United Nations Prevention of Parent-To-Child Transmission (PPTCT) of HIV and Syphilis Task Force meeting was held from 15 to 17 September 2015 in Beijing, China. More than 230 participants from 19 Asia-Pacific countries, including 90 participants from provinces in China, as well as civil society and United Nations partners attended the meeting. The meeting focused on steps towards achieving and validating the elimination of parent-to-child transmission (EPTCT) of infectious diseases, and the integration of services to contribute to improving maternal and child health (MCH) outcomes.
Whether it’s the rising price of the EpiPen, or new outbreaks of diseases, like Ebola, Zika and yellow fever, the rising costs of health technologies and the lack of new tools to tackle health problems, like antimicrobial resistance, is a problem in rich and poor countries alike.
Keywords: TRIPS, Antimicrobial resistance (AMR), health technology, access
The objective of this guideline is to provide a framework for the treatment of Filipino HIV patients using an evidence-based approach, with emphasis on locally available treatment. The target audience is not only the infectious diseases subspecialist who treats HIV but also internists, family physicians, pulmonary specialists and other subspecialists who are taking care of or who wish to care for persons living with HIV.
ART is being rapidly scaled up in Myanmar, led by National AIDS Programme (NAP) and supported by many partners.
Keywords: HIV, ART, PLHIV, NGO, services